Pennant Group Performance degli utili passati
Criteri Il passato verificati 3/6
Pennant Group ha registrato una crescita degli utili a un tasso medio annuo di 35.8%, mentre il settore Healthcare ha registrato utili in crescita a un tasso medio annuo di 2.7%. I ricavi sono stati in crescita a un tasso medio annuo di 18.4%. Il ritorno sul capitale proprio di Pennant Group è 9.1% e ha margini netti di 3%.
Informazioni chiave
35.82%
Tasso di crescita degli utili
31.62%
Tasso di crescita dell'EPS
| Healthcare Crescita del settore | 8.50% |
| Tasso di crescita dei ricavi | 18.45% |
| Rendimento del capitale proprio | 9.12% |
| Margine netto | 2.96% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Articolo di analisi • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
Aggiornamento della narrazione • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.Aggiornamento della narrazione • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Aggiornamento della narrazione • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.
Aggiornamento della narrazione • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Aggiornamento della narrazione • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Aggiornamento della narrazione • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Aggiornamento della narrazione • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Aggiornamento della narrazione • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Aggiornamento della narrazione • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Articolo di analisi • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Aggiornamento della narrazione • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Aggiornamento della narrazione • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Aggiornamento della narrazione • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Articolo di analisi • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Articolo di analisi • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Articolo di analisi • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Articolo di analisi • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Articolo di analisi • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Articolo di analisi • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Articolo di analisi • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Articolo di analisi • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Nuova narrazione • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Articolo di analisi • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Articolo di analisi • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Mar 05
The Pennant Group, Inc. (NASDAQ:PNTG) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 42.2x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Articolo di analisi • Jan 06
Pennant Group (NASDAQ:PNTG) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Pennant Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 1,023 | 30 | 136 | 0 |
| 31 Dec 25 | 948 | 30 | 130 | 0 |
| 30 Sep 25 | 847 | 27 | 122 | 0 |
| 30 Jun 25 | 799 | 27 | 114 | 0 |
| 31 Mar 25 | 748 | 25 | 107 | 0 |
| 31 Dec 24 | 695 | 23 | 102 | 0 |
| 30 Sep 24 | 652 | 21 | 97 | 0 |
| 30 Jun 24 | 612 | 19 | 92 | 0 |
| 31 Mar 24 | 575 | 16 | 88 | 0 |
| 31 Dec 23 | 545 | 13 | 84 | 0 |
| 30 Sep 23 | 524 | 13 | 81 | 0 |
| 30 Jun 23 | 502 | 13 | 77 | 0 |
| 31 Mar 23 | 486 | 7 | 77 | 0 |
| 31 Dec 22 | 473 | 7 | 78 | 0 |
| 30 Sep 22 | 460 | 1 | 80 | 0 |
| 30 Jun 22 | 454 | -3 | 83 | 0 |
| 31 Mar 22 | 448 | 3 | 83 | 0 |
| 31 Dec 21 | 440 | 3 | 81 | 0 |
| 30 Sep 21 | 436 | 9 | 81 | 0 |
| 30 Jun 21 | 422 | 12 | 81 | 0 |
| 31 Mar 21 | 405 | 14 | 77 | 0 |
| 31 Dec 20 | 391 | 16 | 75 | 0 |
| 30 Sep 20 | 372 | 8 | 71 | 0 |
| 30 Jun 20 | 362 | 5 | 64 | 0 |
| 31 Mar 20 | 352 | 4 | 64 | 0 |
| 31 Dec 19 | 339 | 3 | 61 | 0 |
| 30 Sep 19 | 324 | 10 | 57 | 0 |
| 30 Jun 19 | 309 | 13 | 55 | 0 |
| 31 Mar 19 | 296 | 14 | 51 | 0 |
| 31 Dec 18 | 286 | 16 | 49 | 0 |
| 31 Dec 17 | 251 | 10 | 46 | 0 |
| 31 Dec 16 | 217 | 8 | 41 | 0 |
Guadagni di qualità: PNTG ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di PNTG (3%) sono inferiori rispetto allo scorso anno (3.4%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di PNTG sono cresciuti in modo significativo del 35.8% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di PNTG nell'ultimo anno ( 19.2% ) è inferiore alla media quinquennale ( 35.8% all'anno).
Guadagni vs Settore: La crescita degli utili PNTG nell'ultimo anno ( 19.2% ) ha superato la percentuale del settore Healthcare 16%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 9.1% ) di PNTG è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/29 06:36 |
| Prezzo dell'azione a fine giornata | 2026/06/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
The Pennant Group, Inc. è coperta da 8 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |